WO2012154680A3 - MODIFIED AND DERIVATIZED β-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS - Google Patents
MODIFIED AND DERIVATIZED β-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS Download PDFInfo
- Publication number
- WO2012154680A3 WO2012154680A3 PCT/US2012/036795 US2012036795W WO2012154680A3 WO 2012154680 A3 WO2012154680 A3 WO 2012154680A3 US 2012036795 W US2012036795 W US 2012036795W WO 2012154680 A3 WO2012154680 A3 WO 2012154680A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- modified
- derivatized
- compositions
- methods
- glucan compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Abstract
Modified and/or derivativized β-glucans with an enhanced capacity to modulate human immune response as compared to the parent, unmodified and/or underivatized β-glucans are demonstrated.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/115,824 US20140228543A1 (en) | 2011-05-06 | 2012-05-07 | MODIFIED AND DERIVATIZED ß-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161483353P | 2011-05-06 | 2011-05-06 | |
US61/483,353 | 2011-05-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012154680A2 WO2012154680A2 (en) | 2012-11-15 |
WO2012154680A3 true WO2012154680A3 (en) | 2013-02-21 |
Family
ID=47139928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/036795 WO2012154680A2 (en) | 2011-05-06 | 2012-05-07 | MODIFIED AND DERIVATIZED β-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS |
Country Status (2)
Country | Link |
---|---|
US (1) | US20140228543A1 (en) |
WO (1) | WO2012154680A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012167061A1 (en) | 2011-06-03 | 2012-12-06 | Biothera, Inc. | OPSONIZED β-GLUCAN PREPARATIONS AND METHODS |
EP3354319A1 (en) | 2011-09-09 | 2018-08-01 | Biothera, Inc. | Compositions including beta-glucans and methods of use |
US11229701B2 (en) * | 2012-04-30 | 2022-01-25 | Hibercell, Inc. | Methods for identifying beta-glucan binding to immune cells |
JP6163698B2 (en) * | 2013-03-21 | 2017-07-19 | 国立大学法人 千葉大学 | Novel polysaccharide metal complex compound recognizing macrophage mannose receptor and pharmaceutical composition thereof |
WO2015084732A1 (en) | 2013-12-05 | 2015-06-11 | Biothera, Inc. | β-GLUCAN ASSAY METHODS |
EP3851111A1 (en) | 2014-07-10 | 2021-07-21 | Biothera, Inc. | Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment |
JP6887378B2 (en) | 2014-11-06 | 2021-06-16 | バイオセラ,インク. | Beta-glucan methods and compositions that affect the intratumoral microenvironment |
US11815435B2 (en) | 2017-02-24 | 2023-11-14 | Hibercell, Inc. | Beta glucan immunopharmacodynamics |
JP6329302B2 (en) * | 2017-05-10 | 2018-05-23 | 国立大学法人千葉大学 | Novel polysaccharide metal complex compound recognizing macrophage mannose receptor and pharmaceutical composition thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996014873A2 (en) * | 1994-11-16 | 1996-05-23 | Sri International | COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY |
US20060084149A1 (en) * | 2001-03-13 | 2006-04-20 | Taro Kimura | Gene carriers with the use of polysaccharide and process for producing the same |
US20090004201A1 (en) * | 2006-01-17 | 2009-01-01 | Rolf Einar Engstad | Therapy-Enhancing Glucan |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU760669B2 (en) * | 1998-04-28 | 2003-05-22 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
-
2012
- 2012-05-07 WO PCT/US2012/036795 patent/WO2012154680A2/en active Application Filing
- 2012-05-07 US US14/115,824 patent/US20140228543A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996014873A2 (en) * | 1994-11-16 | 1996-05-23 | Sri International | COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY |
US20060084149A1 (en) * | 2001-03-13 | 2006-04-20 | Taro Kimura | Gene carriers with the use of polysaccharide and process for producing the same |
US20090004201A1 (en) * | 2006-01-17 | 2009-01-01 | Rolf Einar Engstad | Therapy-Enhancing Glucan |
Non-Patent Citations (2)
Title |
---|
CLARK, S. M. ET AL.: "Synthetic Entry to Functionalised Morpholine and [1,4]-Oxazepanes via Reductive Amination Reactions of Carbohydrate Derived Dialdehydes.", TET. ASYMM., vol. 15, 2004, pages 3643 - 3652 * |
NUMATA, M. ET AL.: "Polysaccharide-Polynucleotide Complexes (15): Thermal Stability of Schizophyllan(SPG)/Poly(C) Triple Strands Is Controllable by alpha-Amino Acid Modification.", BIOORG. CHEM., vol. 31, 2003, pages 163 - 171 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012154680A2 (en) | 2012-11-15 |
US20140228543A1 (en) | 2014-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012154680A3 (en) | MODIFIED AND DERIVATIZED β-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | |
WO2015010009A3 (en) | Compositions and methods comprising a lipolytic enzyme variant | |
EP3055318A4 (en) | Dihydroxyalkyl substituted polygalactomannan, and methods for producing and using the same | |
EP2675292B8 (en) | Puree compositions having specific carbohydrate ratios and methods for using same | |
BR112013025862A2 (en) | lignin compositions, methods of producing the compositions, methods of using lignin compositions and products thereby produced | |
WO2014197849A3 (en) | Anti-c10orf54 antibodies and uses thereof | |
IL233934B (en) | Cd47 antibodies, compositions comprising the same and uses thereof | |
EP2690951B8 (en) | Cyclodextrin compositions, articles, and methods | |
IL236348A0 (en) | Anti-jagged antibodies, compositions comprising the same and uses thereof | |
WO2011089183A3 (en) | Anticoagulant antidotes | |
WO2012061603A3 (en) | Compositions comprising and methods for forming functionalized carbon-based nanostructures | |
EP3041484A4 (en) | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS | |
EP2983514A4 (en) | Carbohydrate compositions | |
WO2013021279A3 (en) | Highly galactosylated antibodies | |
WO2013142440A3 (en) | Mixtures, methods and compositions pertaining to conductive materials | |
ZA201404634B (en) | Compositions comprising c5 and c6 oligosaccharides | |
IL226383B (en) | Anti-ccl20 antibodies, compositions comprising the same and uses thereof | |
AU2011278165A8 (en) | Adhesive composition including deacetylated chitosan | |
WO2012087327A3 (en) | Polymer systems | |
EP2971030B8 (en) | Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes | |
BR112015010597A2 (en) | drying by mixing nanofibrillated polysaccharide ". | |
WO2012024350A3 (en) | Anti-cancer adenoviruses | |
EP3036264A4 (en) | High molecular weight polymers having high olefin content | |
WO2012064743A3 (en) | Methods for improving heart function | |
WO2012010880A3 (en) | Cellulosic material such as tobacco comprising one or more smoke diluents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12781980 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14115824 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12781980 Country of ref document: EP Kind code of ref document: A2 |